Dear Shareholder,
Throughout the past year, we’ve generated a tremendous amount of positive change and focus throughout the company, which has positioned us to deliver new clinical data across our development pipeline in 2020. Each of our programs continue to build momentum as we move towards our goal of bringing cancer patients with poor prognosis innovative new CAR-T therapies. These advancements speak directly to our position as a leader in the CAR-T cell therapy industry.
This exciting time in Celyad’s history is only possible due to the hard work and dedication of each and every one of our team members, patients, physicians and collaborators. And of course, we must thank you, our shareholders, for your continued support and investment in the company as we look towards continued success and progress in 2020 and beyond.
